JP2008543878A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543878A5
JP2008543878A5 JP2008517207A JP2008517207A JP2008543878A5 JP 2008543878 A5 JP2008543878 A5 JP 2008543878A5 JP 2008517207 A JP2008517207 A JP 2008517207A JP 2008517207 A JP2008517207 A JP 2008517207A JP 2008543878 A5 JP2008543878 A5 JP 2008543878A5
Authority
JP
Japan
Prior art keywords
peptide agent
use according
terminal
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023759 external-priority patent/WO2006138708A1/en
Publication of JP2008543878A publication Critical patent/JP2008543878A/ja
Publication of JP2008543878A5 publication Critical patent/JP2008543878A5/ja
Pending legal-status Critical Current

Links

JP2008517207A 2005-06-17 2006-06-19 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物 Pending JP2008543878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US77694706P 2006-02-28 2006-02-28
PCT/US2006/023759 WO2006138708A1 (en) 2005-06-17 2006-06-19 Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized

Publications (2)

Publication Number Publication Date
JP2008543878A JP2008543878A (ja) 2008-12-04
JP2008543878A5 true JP2008543878A5 (https=) 2011-10-20

Family

ID=37570786

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008517206A Pending JP2008543877A (ja) 2005-06-17 2006-06-19 Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
JP2008517207A Pending JP2008543878A (ja) 2005-06-17 2006-06-19 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物
JP2008517208A Withdrawn JP2008543879A (ja) 2005-06-17 2006-06-19 Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物ならびに方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008517206A Pending JP2008543877A (ja) 2005-06-17 2006-06-19 Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008517208A Withdrawn JP2008543879A (ja) 2005-06-17 2006-06-19 Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物ならびに方法

Country Status (11)

Country Link
US (8) US20090131313A1 (https=)
EP (4) EP1904080A4 (https=)
JP (3) JP2008543877A (https=)
KR (3) KR20080021782A (https=)
CN (1) CN105106931A (https=)
AU (3) AU2006261156B2 (https=)
CA (3) CA2612410A1 (https=)
HK (1) HK1218248A1 (https=)
IL (4) IL187522A0 (https=)
MX (3) MX2007015956A (https=)
WO (3) WO2006138707A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2011044589A2 (en) * 2009-10-09 2011-04-14 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
AU2014345802B2 (en) * 2013-11-07 2018-01-25 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
WO2015138604A1 (en) 2014-03-12 2015-09-17 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
WO2016064078A1 (ko) 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
KR102487614B1 (ko) 2015-10-06 2023-01-12 에이치엘비테라퓨틱스 주식회사 티모신 β4를 포함하는 안약의 제조방법
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
KR102115158B1 (ko) * 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
BR112019017275A2 (pt) 2017-02-21 2020-05-12 Tearsolutions, Inc. Composições peptídicas estáveis
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
JP2021504349A (ja) * 2017-11-24 2021-02-15 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
CA3260743A1 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and their methods of use for the treatment of eye symptoms related to moderate/severe dry eye

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
AU2001292881A1 (en) * 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20060263360A1 (en) * 2003-03-31 2006-11-23 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Similar Documents

Publication Publication Date Title
JP2008543878A5 (https=)
AU634954B2 (en) Treatment of diabetes mellitus
KR102213907B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
KR102255479B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
US20200289653A1 (en) Improved peptide pharmaceuticals for insulin resistance
CN102292346B (zh) 肥胖的治疗
KR102542164B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
KR20240128130A (ko) 펩티드 wkdeagkplvk를 포함하는 조성물
CN116322739A (zh) Glp-1r激动剂/fgf21融合蛋白
CN110300595A (zh) Pac1受体激动剂(maxcap)及其用途
CN103391786B (zh) 作为抗糖尿病肽的载脂蛋白a-iv
US12552848B2 (en) Hydrochloride salts of C5a receptor agonist peptides
WO2018188565A1 (zh) 用于治疗代谢系统疾病的多肽及其组合物
JP3260760B2 (ja) ヒルジンを含んでなる医薬組成物
CN116113639A (zh) 活性降低的glp-1r激动肽
JP3350604B2 (ja) ヒルジン含有医薬組成物
EP3402505B1 (en) Pharmaceutical formulations for the treatment of diabetes
CN104592380A (zh) 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
CN104045703A (zh) 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
TW202607013A (zh) 一種包含ｐｓｄ－９５多肽抑制劑的醫藥組成物及其製備方法
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
US20210171604A1 (en) Peptides for the treatment of type 2 diabetes
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus